Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “hold” rating reiterated by analysts at Evercore ISI in a research note issued on Monday. They presently have a $105.00 price objective on the medical research company’s stock. Evercore ISI’s target price would suggest a potential upside of 25.15% from the company’s previous close.

A number of other equities analysts also recently issued reports on EW. Zacks Investment Research downgraded Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a report on Friday, October 28th. Jefferies Group reiterated a “buy” rating and issued a $115.00 price objective (down previously from $125.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, October 26th. RBC Capital Markets reiterated an “outperform” rating and issued a $123.00 price objective (down previously from $130.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, October 26th. Northland Securities upgraded Edwards Lifesciences Corp. from a “market perform” rating to an “outperform” rating and set a $105.00 price objective for the company in a research note on Tuesday, November 8th. Finally, Stifel Nicolaus reduced their price objective on Edwards Lifesciences Corp. from $122.00 to $114.00 and set a “buy” rating for the company in a research note on Wednesday, October 26th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $117.28.

Analyst Recommendations for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) opened at 83.90 on Monday. The firm’s 50-day moving average is $99.49 and its 200-day moving average is $106.55. The stock has a market capitalization of $17.94 billion, a price-to-earnings ratio of 33.16 and a beta of 0.71. Edwards Lifesciences Corp. has a 52-week low of $72.20 and a 52-week high of $121.75.

Edwards Lifesciences Corp. (NYSE:EW) last announced its quarterly earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.68. The firm earned $739.40 million during the quarter, compared to the consensus estimate of $749.14 million. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.54 earnings per share. Analysts predict that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corp. (EW) Stock Rating Reaffirmed by Evercore ISI” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/edwards-lifesciences-corp-ew-stock-rating-reaffirmed-by-evercore-isi.html.

In other news, VP Donald E. Bobo, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $115.78, for a total value of $2,084,040.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $84.67, for a total value of $4,157,297.00. The disclosure for this sale can be found here. 2.37% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. increased its stake in shares of Edwards Lifesciences Corp. by 62.3% in the second quarter. Ameriprise Financial Inc. now owns 4,253,976 shares of the medical research company’s stock valued at $424,200,000 after buying an additional 1,632,567 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Edwards Lifesciences Corp. by 83.1% in the second quarter. American Century Companies Inc. now owns 1,423,750 shares of the medical research company’s stock valued at $141,991,000 after buying an additional 646,142 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Edwards Lifesciences Corp. during the second quarter valued at approximately $58,912,000. 1832 Asset Management L.P. bought a new stake in shares of Edwards Lifesciences Corp. during the third quarter valued at approximately $67,325,000. Finally, Capital Fund Management S.A. increased its stake in shares of Edwards Lifesciences Corp. by 10,543.8% in the second quarter. Capital Fund Management S.A. now owns 473,012 shares of the medical research company’s stock valued at $47,173,000 after buying an additional 468,568 shares during the last quarter. Institutional investors own 83.08% of the company’s stock.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.